Therefore, the authors delicately designed and synthesized a multiparatopic VEGF decoy receptor (Ate-Grab), a fusion protein consisting of single-chain Fv of atezolizumab for targeting PD-L1-rich tumor tissues, fused to VEGF-Grab, which was previously developed to target PIGF/VEGF96, resulting in PD-L1-directed PlGF/VEGF blockade. The gene discussed is VEGFA; the disease is neoplasm.